A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial

Autor:	E Kabouraki, John Souglakos, D. Mavroudis, Z. Saridaki, L. Vamvakas, N Vardakis, Dora Hatzidaki, V. Georgoulias, Alexandra Voutsina, Konstantinos Kalbakis, Nikos Androulakis
Jazyk:	angličtina
Rok vydání:	2012
Předmět:	Oncology Adult Male Cancer Research medicine.medical_specialty Organoplatinum Compounds Leucovorin Cetuximab Pilot Projects medicine.disease_cause Antibodies Monoclonal Humanized Gastroenterology Drug Administration Schedule Proto-Oncogene Proteins p21(ras) Internal medicine Proto-Oncogene Proteins Antineoplastic Combined Chemotherapy Protocols medicine Biomarkers Tumor Hepatectomy Humans FOLFOXIRI Aged business.industry metastatic colorectal cancer Liver Neoplasms Antibodies Monoclonal Middle Aged medicine.disease Oxaliplatin Irinotecan Treatment Outcome Fluorouracil Clinical Study ras Proteins Camptothecin Female KRAS business Colorectal Neoplasms Progressive disease Febrile neutropenia medicine.drug
Zdroj:	British Journal of Cancer
ISSN:	1532-1827 0007-0920
Popis:	Background: We conducted an open-label, pilot phase II trial to evaluate the efficacy and safety of FOLFOXIRI plus cetuximab as first-line treatment of patients with metastatic colorectal cancer (mCRC). Methods: Thirty patients with KRAS wild-type mCRC
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::740c2faacefc7206f74d664196f62f3a http://europepmc.org/articles/PMC3516691 Zobrazit plný text záznamu Plný text ve formátu PDF